Not exact matches
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required
on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global
macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further
development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact
on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
He focuses
on delivering asset allocation strategies and analysis of the overall
macroeconomic and political landscape as defined by fundamentals, market sentiment and technical
developments in the charts.
Professor Sachs is widely considered to be one of the world's leading experts
on economic
development, global
macroeconomics, and the fight against poverty.
She is fluent in Mandarin and is currently the research director of J Capital, a company that works for foreign investors in China doing fundamental research
on local companies and tracking
macroeconomic developments.
He focuses
on delivering analysis of monetary policies and
macroeconomic developments globally as defined by fundamentals, market sentiment and technical analysis.
He focuses
on delivering strategies and analyses in the currency market as defined by fundamentals, changes in
macroeconomic themes, and technical
developments.
The Deputy Head of
Macroeconomic Research Unit, Ministry of Finance, Dr. Millicent deGraft - Johnson who spoke on the governments short to medium - term development programme said it was aimed at providing opportunities for growth and job creation through the private sector, and had developed concrete reform actions to tackle key challenges to private investment such as ensuring macroeconomic stability and debt sustainability, improving the ease of doing business and enhancing access to affordable and long - term financing and de-risking
Macroeconomic Research Unit, Ministry of Finance, Dr. Millicent deGraft - Johnson who spoke
on the governments short to medium - term
development programme said it was aimed at providing opportunities for growth and job creation through the private sector, and had developed concrete reform actions to tackle key challenges to private investment such as ensuring
macroeconomic stability and debt sustainability, improving the ease of doing business and enhancing access to affordable and long - term financing and de-risking
macroeconomic stability and debt sustainability, improving the ease of doing business and enhancing access to affordable and long - term financing and de-risking instruments.
Also speaking
on UBA's financial performance and position, the Group Chief Finance Officer (GCFO), Mr. Ugo Nwaghodoh said «amidst
macroeconomic volatilities, we leveraged efficiency gains in our business
development and operations to grow earnings.
«These
macroeconomic vulnerabilities and the option to tackle those weaknesses hinged
on two key areas: mobilise domestic resources to finance social spending and infrastructural
development and the ability to embark
on reforms that will stimulate private sector for investment in order to accelerate growth and job creation,» Dr Bawumia said.
Yield curves change shape as the economic situation evolves, based
on developments in
macroeconomic factors like interest rates, inflation, industrial output, GDP figures and balance of trade.
According to Flassbeck, the former Director of
Macroeconomics and
Development at the UNCTAD in Geneva and a former State Secretary of Finance, a recent period of extremely low solar and wind power generation shows that Germany will never be able to rely
on renewable energy, regardless of how much new capacity will be built.
These
macroeconomic developments have ramped up the pressure
on labour markets across the world.
Federal Reserve Bank of NY About Blog The New York Fed's Liberty Street Economics blog provides commentary
on current economic topics relating to monetary policy,
macroeconomic developments, financial stability issues, and regional trends in the Second Federal Reserve District.
This one - day forum will focus
on the
macroeconomic trends and the effects they have had
on real estate investments and
developments within the healthcare sector.
Building
on the success of the first Emerging Markets Summit, the Summit takes a fresh look at the risks and rewards of emerging market investments in light of recent
macroeconomic and geopolitical
developments.